#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant central nervous system neoplasm Immune-mediated myositis Immunodeficiency congenital Medulloblastoma recurrent Small intestine leiomyosarcoma Neuropathy peripheral Extra-osseous Ewing's sarcoma metastatic Keratosis follicular Anaplastic thyroid cancer Epstein-Barr virus associated lymphoproliferative disorder Penile cancer Transferrin decreased Malignant melanoma Cold type haemolytic anaemia Immunoglobulin G4 related disease More trials…

    Learn about Rare Diseases

    Turner’s syndrome – Life with Disease Paroxysmal nocturnal haemoglobinuria Andersen-Tawil syndrome – Life with Disease Sarcoidosis – Life with Disease Breast angiosarcoma metastatic – Trials in Disease Undifferentiated sarcoma – Treatment Pelizaeus-Merzbacher disease – Diagnostics Chondrosarcoma – Treatment Haemophilia A without inhibitors Glomerulonephritis membranoproliferative More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    PRILOCAINE HYDROCHLORIDE Neflamapimod Rondaptivon Pegol Olopatadine Digitoxin Bleomycin Estradiol Hemihydrate Davutamig INSULIN DEGLUDEC Golexanolone HSP-CAR19M Favezelimab Hydrocortisone Ph. Eur. Indacaterol Maleate ACARBOSE Sorafenib Tosilate ZOLPIDEM TARTRATE Desogestrel Mk-0616 Clodronate Disodium More therapies…

    Learn about Your Condition

    Adrenogenital syndrome Follicular lymphoma stage III Insomnia Facial paresis Alveolar proteinosis Stress cardiomyopathy Hepatitis alcoholic Rectal neoplasm Bile duct cancer Type 1 diabetes mellitus Thymoma Neurodermatitis Cardiovascular disorder Lymphocytic leukaemia Endocarditis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Testing the Safety and Effects of TUB-030 in Patients with Advanced Head and Neck Cancer or Non-Small-Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    • Non-small cell lung cancer
    Investigated Drugs:
    • TUB-030
    France Romania Spain

  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Carboplatin
    • Cisplatin
    Belgium France Germany Greece Italy Poland +3

  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Adenocarcinoma pancreas
    • Non-small cell lung cancer
    Investigated Drugs:
    • 177LU-FAP-2286
    • Calcium Folinate
    • Fluorouracil
    Belgium France Italy Spain

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Vinorelbine
    • Cemiplimab
    Hungary Poland Portugal Romania Spain

  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cemiplimab
    Austria Estonia France Germany Ireland Italy +1

  • Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pembrolizumab
    Greece Hungary Poland Romania Spain
Previous Page
1 … 3 4 5 6 7 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!